USFDA inspections of Indian sites still below pre-Covid-19 levels

With US Food and Drug Administration (USFDA) scrutiny of Indian pharmaceutical (pharma) plants rising, analysts point out that Indian sites have had a 9 per cent share of total global inspections. While the pace of inspections has been on the rise since calendar year 2020 (CY20), it’s still significantly below pre-pandemic levels.

According to an analysis by India Ratings & Research (Ind-Ra), Indian pharma was exposed to an average of 9 per cent of overall global inspections from calendar year 2009 (CY09) to the first quarter (Q1) of 2022-23 (FY23).

“According to USFDA data, Indian pharma was exposed to an